Founders selling stock during lockup expiration: apparently surprising to people who've never seen an IPO before.
SpaceX shares dropped 5% on September 9 as approximately 319 million insider-held shares became available for sale, representing up to $47.2 billion in potential selling pressure. The broader space sector followed suit with predictable obedience—AST SpaceMobile fell 4%, Rocket Lab slipped 2%—proving once again that investor enthusiasm for Mars exploration has a floor price somewhere just below these particular prices.
The unlock itself wasn't a surprise. SpaceX's own IPO prospectus disclosed it plainly. The company went public in June 2026 at $135 per share, raising approximately $75 billion and hitting a valuation near $1.8 trillion. Shares spiked initially, pushing SpaceX briefly past both Amazon and Microsoft in market cap—a moment of pure mathematical nonsense that lasted roughly as long as a CFO's unforced confidence. The stock peaked at $225.64 intraday on June 16, then declined in three consecutive sessions. By the time the September unlock arrived, the stock had already lost ground. The 5% drop on September 9 was less a shock and more a tired inevitability.
What makes this interesting isn't the selling itself—insiders selling at higher valuations is the oldest story in equities. It's the valuation framework that makes the selling look like panic rather than prudence. SpaceX trades at a price-to-sales ratio of 86.9, derived from a $2 trillion market capitalization against $23 billion in trailing twelve-month revenue. That multiple hasn't inspired confidence so much as it has invited scrutiny. For context, that's the valuation math you get when investors decide that AI infrastructure spending—SpaceX burned $15.8 billion on AI compute in Q2 alone—is somehow the pathway to profitability rather than a gigantic ongoing liability.
The June IPO created an oddly-shaped float from day one. SpaceX started with only 4 to 5% of shares available to trade post-IPO, a scarcity designed to juice the opening price. The September unlock brought that to roughly 16%. More importantly, it brought the question into sharp focus: what happens when the free float expands and there's nothing underneath the valuation except hope and Elon Musk's 6.4 billion shares, locked up until June 2027?
The Morning Brief
Enjoying this? Get it in your inbox.
The company itself isn't a mystery. SpaceX's first earnings report—filed in connection with the IPO—showed revenue growth and the capital intensity of running a space launch business combined with an AI infrastructure build. It also showed the company remains unprofitable, a detail that markets briefly noticed before deciding it was irrelevant. The staggered lockup schedule, which spreads insider sales across multiple dates through December 2026, ensures that valuation recalibration will occur incrementally rather than all at once. It's a softer landing than a single drop, assuming the buyers keep showing up.
AST SpaceMobile and Rocket Lab didn't collapse because their fundamentals changed on September 9. They fell because the sector's largest company just demonstrated that founder confidence and actual selling pressure are two different things. When the biggest fish in the tank starts moving toward the exit, the smaller fish don't need to know the reason. They only need to know what it looks like.
The market's convenient memory loss—the shock at seeing insiders sell stock during a scheduled unlock—is the real story. Anyone who's watched an IPO knows how this works. The surprise isn't that it's happening. It's that we keep acting like it is.
Subscriber Only
Subscribe to The Alignment Times and get every article delivered to your inbox.
Photo by Rafael Minguet Delgado via Pexels
Rex Volkov
Staff writer covering financial markets and corporate strategy. Has strong opinions about spreadsheets.
Committee Agrees To Agree To Reconvene And Consider Agreeing Later
Apr 6, 2026
Company That Sells Shovels Reports Everyone Still Digging
Apr 6, 2026
Strong Dollar Continues Tradition of Being Inconvenient For Everyone Else
Apr 4, 2026